L. Yunusova, J. Rizaev, T. Aoyama, S. Mamarajabov, Dilorom Djakhangirova, J. Sakamoto, J. Shukurov, Kamronbek J. Olimjonov
{"title":"MAGNETIC RESONANCE IMAGING IN THE DIAGNOSIS OF CYSTIC LESIONS OF THE NECK","authors":"L. Yunusova, J. Rizaev, T. Aoyama, S. Mamarajabov, Dilorom Djakhangirova, J. Sakamoto, J. Shukurov, Kamronbek J. Olimjonov","doi":"10.4993/ACRT.29.102","DOIUrl":"https://doi.org/10.4993/ACRT.29.102","url":null,"abstract":"","PeriodicalId":35647,"journal":{"name":"Annals of Cancer Research and Therapy","volume":"29 1","pages":"102-109"},"PeriodicalIF":0.0,"publicationDate":"2021-01-08","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"49372643","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Ara-C is one of the antineoplastic drugs, immune suppressants and a pyrimidine nucleoside. Though Ara-C is an impor- tant drug in the treatment of acute myeloid leukemia (AML), there are encouraged consequences about the therapeutic capa-bility of Ara-C in acute lymphoblastic leukemia (ALL). Herein, we evaluated the effect of Ara-C on the expression of genes coding for the enzymes DNA methyltransferase (DNMT) 3A, DNMT 3B and histone deacetylase 3 (HDAC3) in the human B cell-ALL cell line Nalm6. Moreover, we investigated its effects on Nalm6 cells proliferation and apoptosis. Briefly, Nalm6 cells and also normal peripheral blood mononuclear cells (PBMCs) were grown in RPMI 1640 medium supplemented with 10% fetal bovine serum, and treated with Ara-C at their exponential growth phase. Cell apoptosis rates were studied using Annexin-V/PI staining and fluorescence-activated cell sorting (FACS) analysis, and their proliferation levels were evaluated upon treatment with increasing concentration of Ara-C (5–80 nM) by MTT assay. Finally, the expressions of the above- mentioned 3 genes were quantified using real-time PCR. Based on analysis, Ara-C could powerfully trigger apoptosis and obstructs proliferation of Nalm6 cells upon treatment. After Ara-C treatment, expressions of the genes DNMT3A in Nalm6 cell line increased but DNMT3B and HDAC3 decreased significantly compared with the control group. Altered expressions of the above-mentioned genes in ALL cells under the effect of Ara-C suggests that epigenetic changes such as DNA hyper- methylation and histone deacetylation may be appropriate goals in the development of new therapies.
{"title":"Ara-C elicits apoptosis and inhibits proliferation of human lymphoblastic leukemia Nalm6 cell lines by down regulation of HDAC3 and DNMT3B and up regulation of DNMT3A","authors":"S. Moghadasi, F. Pourrajab, S. Hekmatimoghaddam","doi":"10.4993/ACRT.29.47","DOIUrl":"https://doi.org/10.4993/ACRT.29.47","url":null,"abstract":"Ara-C is one of the antineoplastic drugs, immune suppressants and a pyrimidine nucleoside. Though Ara-C is an impor- tant drug in the treatment of acute myeloid leukemia (AML), there are encouraged consequences about the therapeutic capa-bility of Ara-C in acute lymphoblastic leukemia (ALL). Herein, we evaluated the effect of Ara-C on the expression of genes coding for the enzymes DNA methyltransferase (DNMT) 3A, DNMT 3B and histone deacetylase 3 (HDAC3) in the human B cell-ALL cell line Nalm6. Moreover, we investigated its effects on Nalm6 cells proliferation and apoptosis. Briefly, Nalm6 cells and also normal peripheral blood mononuclear cells (PBMCs) were grown in RPMI 1640 medium supplemented with 10% fetal bovine serum, and treated with Ara-C at their exponential growth phase. Cell apoptosis rates were studied using Annexin-V/PI staining and fluorescence-activated cell sorting (FACS) analysis, and their proliferation levels were evaluated upon treatment with increasing concentration of Ara-C (5–80 nM) by MTT assay. Finally, the expressions of the above- mentioned 3 genes were quantified using real-time PCR. Based on analysis, Ara-C could powerfully trigger apoptosis and obstructs proliferation of Nalm6 cells upon treatment. After Ara-C treatment, expressions of the genes DNMT3A in Nalm6 cell line increased but DNMT3B and HDAC3 decreased significantly compared with the control group. Altered expressions of the above-mentioned genes in ALL cells under the effect of Ara-C suggests that epigenetic changes such as DNA hyper- methylation and histone deacetylation may be appropriate goals in the development of new therapies.","PeriodicalId":35647,"journal":{"name":"Annals of Cancer Research and Therapy","volume":" ","pages":""},"PeriodicalIF":0.0,"publicationDate":"2021-01-08","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"42322189","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Background: Prostate cancer is a momentous health problem worldwide. Prostate cancer in Sudan is the third most com- mon cancer type. The role of human epidermal growth factor receptor 2 (HER2/neu) in prostatic tumors is still not fully understood. The findings of studies testing the association between HER2/neu expression and prostate cancer have been inconsistent. Objectives: To demonstrate the association between ages, epidermal growth factor receptor 2 and prostate cancer. Design: Retrospective. Settings: Sudan University for Science and Technology and National Health Laboratory (NHL) in Khartoum state Republic of Sudan. Patients and methods: Two paraffin sections were taken, one stained with Haematoxylin and Eosin to confirm the diag- nosis, the other stained using primary antibodies to HER2 protein with immunohistochemistry method using the DAKO Hercep Test TM protocol. Sample size: Forty-six paraffin blocks were included in this study; 36 specimens were medium-grade and high-grade can- cers and ten specimens were low-grade cancer. Results: The mean age of the study group was 64 years. Prostatic cancer grades revealed, 10 (21.7%) patients with Gleason Group = 3 + 3, 2 (4.3%) patients with Gleason Group = 3 + 4, 11 (23.9%) patients with Gleason Group = 4 + 3, and 23 (50%) patients with Gleason Group = 4 + 4. Positive Her2 was found to be associated with high-grade (GG8) and medium-grade (GG7) compared to low-grade prostatic cancer (GG6). Conclusions: The current study was a clue for a possible association between HER2/neu and prostatic cancer, and further studies might elucidate this connection.
背景：前列腺癌症是世界范围内一个重大的健康问题。在苏丹，癌症是第三常见的癌症类型。人类表皮生长因子受体2（HER2/neu）在前列腺肿瘤中的作用尚不完全清楚。检测HER2/neu表达与前列腺癌症之间相关性的研究结果不一致。目的：探讨年龄、表皮生长因子受体2与前列腺癌症的关系。设计：回顾性。地点：苏丹共和国喀土穆的苏丹科技大学和国家卫生实验室。患者和方法：取两个石蜡切片，一个用苏木精和曙红染色以确认诊断，另一个用HER2蛋白的一级抗体染色，免疫组织化学方法使用DAKO Hercep Test TM方案。样本量：本研究包括四十六个石蜡块；36例标本为中粒级和高级别癌症，10例标本为低级别癌症。结果：研究组的平均年龄为64岁。前列腺癌症分级显示，10名（21.7%）格里森组患者=3+3，2名（4.3%）格里森小组患者=3+4，11名（23.9%）格里森集团患者=4+3，23名（50%）格里森群组患者=4+4。与低级别前列腺癌症（GG6）相比，Her2阳性与高级别（GG8）和中级别（GG7）相关。结论：目前的研究为HER2/neu与癌症之间的可能联系提供了线索，进一步的研究可能会阐明这种联系。
{"title":"An Association Between Human Epidermal Growth Factor Receptor 2 and Prostate Cancer","authors":"M. Salih","doi":"10.4993/ACRT.29.17","DOIUrl":"https://doi.org/10.4993/ACRT.29.17","url":null,"abstract":"Background: Prostate cancer is a momentous health problem worldwide. Prostate cancer in Sudan is the third most com- mon cancer type. The role of human epidermal growth factor receptor 2 (HER2/neu) in prostatic tumors is still not fully understood. The findings of studies testing the association between HER2/neu expression and prostate cancer have been inconsistent. Objectives: To demonstrate the association between ages, epidermal growth factor receptor 2 and prostate cancer. Design: Retrospective. Settings: Sudan University for Science and Technology and National Health Laboratory (NHL) in Khartoum state Republic of Sudan. Patients and methods: Two paraffin sections were taken, one stained with Haematoxylin and Eosin to confirm the diag- nosis, the other stained using primary antibodies to HER2 protein with immunohistochemistry method using the DAKO Hercep Test TM protocol. Sample size: Forty-six paraffin blocks were included in this study; 36 specimens were medium-grade and high-grade can- cers and ten specimens were low-grade cancer. Results: The mean age of the study group was 64 years. Prostatic cancer grades revealed, 10 (21.7%) patients with Gleason Group = 3 + 3, 2 (4.3%) patients with Gleason Group = 3 + 4, 11 (23.9%) patients with Gleason Group = 4 + 3, and 23 (50%) patients with Gleason Group = 4 + 4. Positive Her2 was found to be associated with high-grade (GG8) and medium-grade (GG7) compared to low-grade prostatic cancer (GG6). Conclusions: The current study was a clue for a possible association between HER2/neu and prostatic cancer, and further studies might elucidate this connection.","PeriodicalId":35647,"journal":{"name":"Annals of Cancer Research and Therapy","volume":" ","pages":""},"PeriodicalIF":0.0,"publicationDate":"2021-01-08","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"47896352","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Recently, flavonoid quercetin is described as a natural product capable of the treatment of various types of leukemia, such as acute myeloid leukemia (AML), by targeting various survival and proliferation-associated signaling pathways or molecules. Herein, we evaluated the anti-leukemic effects of the quercetin on the human AML cell line, U937. Accordingly, the proliferation rate of the U937 cells was examined using MTT assay at 6, 12, and 24 hours of treatment with a series of quercetin concentrations, including 10, 20, 30, 40, 80, and 120 µM. Moreover, the apoptosis rates of U937 cells were estimated 6, 12, and 24 hours after exposure to quercetin 30 µM using annexin-V/PI staining and fluorescence-activated cell sorting (FACS) analysis. Finally, the expression rates of survivin, Mcl-1, XIAP, Bcl-2, and Bax were measured after treatment with quercetin 20 and 40 µM using Real-Time PCR within 6 and 12 hours of treatment. Concerning results, quercetin induced significant apoptosis in U937 cells within 6, 12, and 24 hours of treatment. Moreover, results verified the inhibitory effect of quercetin on U937 cell proliferation, more powerfully at 24 hours of exposure. Additionally, quercetin robustly modified Mcl-1, XIAP, and survivin expression at mRNA levels without any effect on Bax expression. Besides, this flavonoid stimu- lated slight but significant inhibitory effects on Bcl-2 expression at mRNA levels. In sum, the encouraging consequences of using quercetin toward the U937 cells have made it a favorable compound for treating AML through the downregulation of anti-apoptotic proteins.
{"title":"Anti-leukemic effects of the quercetin on human leukemia U937 cells mediated by down-regulation of Mcl-1, survivin, and XIAP","authors":"M. Rahbaran, Ehsan Razeghian","doi":"10.4993/ACRT.29.55","DOIUrl":"https://doi.org/10.4993/ACRT.29.55","url":null,"abstract":"Recently, flavonoid quercetin is described as a natural product capable of the treatment of various types of leukemia, such as acute myeloid leukemia (AML), by targeting various survival and proliferation-associated signaling pathways or molecules. Herein, we evaluated the anti-leukemic effects of the quercetin on the human AML cell line, U937. Accordingly, the proliferation rate of the U937 cells was examined using MTT assay at 6, 12, and 24 hours of treatment with a series of quercetin concentrations, including 10, 20, 30, 40, 80, and 120 µM. Moreover, the apoptosis rates of U937 cells were estimated 6, 12, and 24 hours after exposure to quercetin 30 µM using annexin-V/PI staining and fluorescence-activated cell sorting (FACS) analysis. Finally, the expression rates of survivin, Mcl-1, XIAP, Bcl-2, and Bax were measured after treatment with quercetin 20 and 40 µM using Real-Time PCR within 6 and 12 hours of treatment. Concerning results, quercetin induced significant apoptosis in U937 cells within 6, 12, and 24 hours of treatment. Moreover, results verified the inhibitory effect of quercetin on U937 cell proliferation, more powerfully at 24 hours of exposure. Additionally, quercetin robustly modified Mcl-1, XIAP, and survivin expression at mRNA levels without any effect on Bax expression. Besides, this flavonoid stimu- lated slight but significant inhibitory effects on Bcl-2 expression at mRNA levels. In sum, the encouraging consequences of using quercetin toward the U937 cells have made it a favorable compound for treating AML through the downregulation of anti-apoptotic proteins.","PeriodicalId":35647,"journal":{"name":"Annals of Cancer Research and Therapy","volume":" ","pages":""},"PeriodicalIF":0.0,"publicationDate":"2021-01-08","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"45361475","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
M. Vahidi, A. Noroozi-aghideh, Atefeh Entezari, M. Zamani, Y. Yaghoubi, A. Hassanzadeh, Adel Naimi
{"title":"Quercetin elicits proapoptotic effect through downregulation of antiapoptotic and upregulation of proapoptotic genes in human myeloid leukemia KG-1 cells","authors":"M. Vahidi, A. Noroozi-aghideh, Atefeh Entezari, M. Zamani, Y. Yaghoubi, A. Hassanzadeh, Adel Naimi","doi":"10.4993/ACRT.29.96","DOIUrl":"https://doi.org/10.4993/ACRT.29.96","url":null,"abstract":"","PeriodicalId":35647,"journal":{"name":"Annals of Cancer Research and Therapy","volume":"29 1","pages":"96-101"},"PeriodicalIF":0.0,"publicationDate":"2021-01-08","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"43412694","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Heyam A. Awad, Eman M. Krishan, Ahmad M. Abdulraheem, Mohammed M. Abu Jubba, Zaid S. Al-khateeb, Fatima Obeidat
Objective: The earliest histopathological feature of celiac disease (CD) is increased intraepithelial lymphocytes (IEL). The aim of this study is to find out the normal IEL count and to describe the histopathological features of CD among Jordanian population. Methods: This retrospective cohort study included 207 patients, 99 with CD cases and 108 normal controls. IEL were counted in all cases and controls. Histopathological features including villous atrophy and crypt hyperplasia were evaluated in CD cases and were classified according to the Modified Marsh classification. A two-tailed t-test was used to compare the means of variables and a P value of <0.05 was considered significant. Pearson correlation was used to measure relationships between histopathological features in CD cases. The cut-off point was suggested as the mean of normal+ 2 standard deviations (SD). Results: The mean number of IEL in normal biopsies is 11.7. The upper limit of normal is 17, this figure (17) is also the mean + 2SDs. There is no statistical difference of the number of IEL between males and females in the normal group (p = 0.54) or the CD group (p = 0.807). The number of normal IEL significantly decreases with higher age of 49 (p = 0.034). Conclusion: Using 17 as a cut-off point is sufficient to detect CD. Higher thresholds result in missing cases. The cut off points of IEL can vary among geographical areas and thresholds should take these differences into account.
{"title":"Normal intraepithelial lymphocyte counts in duodenal biopsies and histological features of celiac disease among Jordanian adults","authors":"Heyam A. Awad, Eman M. Krishan, Ahmad M. Abdulraheem, Mohammed M. Abu Jubba, Zaid S. Al-khateeb, Fatima Obeidat","doi":"10.4993/ACRT.29.62","DOIUrl":"https://doi.org/10.4993/ACRT.29.62","url":null,"abstract":"Objective: The earliest histopathological feature of celiac disease (CD) is increased intraepithelial lymphocytes (IEL). The aim of this study is to find out the normal IEL count and to describe the histopathological features of CD among Jordanian population. Methods: This retrospective cohort study included 207 patients, 99 with CD cases and 108 normal controls. IEL were counted in all cases and controls. Histopathological features including villous atrophy and crypt hyperplasia were evaluated in CD cases and were classified according to the Modified Marsh classification. A two-tailed t-test was used to compare the means of variables and a P value of <0.05 was considered significant. Pearson correlation was used to measure relationships between histopathological features in CD cases. The cut-off point was suggested as the mean of normal+ 2 standard deviations (SD). Results: The mean number of IEL in normal biopsies is 11.7. The upper limit of normal is 17, this figure (17) is also the mean + 2SDs. There is no statistical difference of the number of IEL between males and females in the normal group (p = 0.54) or the CD group (p = 0.807). The number of normal IEL significantly decreases with higher age of 49 (p = 0.034). Conclusion: Using 17 as a cut-off point is sufficient to detect CD. Higher thresholds result in missing cases. The cut off points of IEL can vary among geographical areas and thresholds should take these differences into account.","PeriodicalId":35647,"journal":{"name":"Annals of Cancer Research and Therapy","volume":" ","pages":""},"PeriodicalIF":0.0,"publicationDate":"2021-01-08","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"42377626","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
R. Subedi, U. Joshi, Sagar Gyawali, V. Agrawal, Asmita Parajuli
Introduction: Copanlisib is an intravenous pan-class I PI3K inhibitor with predominant activity against the α and δ isoforms. We conducted this review to assess the efficacy and safety of copanlisib in patients with relapsed or refractory nonHodgkin’s lymphoma (NHL) and other solid tumors. Methods: A systematic search of the electronic database (PubMed, Cochrane, Clinicaltrials.gov, Google scholar, and China National Knowledge Infrastructure) was conducted for relevant studies. Any clinical trial with clear outcome measures on the efficacy or safety of copanlisib in NHL or other solid tumors were eligible for inclusion. The objective response rate (ORR) and the complete response (CR) rate were used to assess the efficacy. Incidence of all grade and grade 3–4 treatmentemergent adverse events (TEAE) were calculated to evaluate the safety profile. Results: We analyzed seven single-arm prospective clinical trials. The pooled ORR was 39.1% (95% CI: 21.0–60.7%) for NHL cohort. The pooled CR rate for NHL was 10.9% (95% CI: 6.9–16.8%). Indolent NHL had a higher rate of response than aggressive NHL (ORR 56.9% vs. 22.8%; CR rate 15.8% vs. 7.6%). The pooled incidence rate of grade 3–4 TEAE was 73.9% (95% CI: 66.4–80.3%). Most common grade 3–4 TEAE were: hyperglycemia (31.4%), hypertension (29.8%), neutropenia (18.3%), anemia (7.4%), and pneumonia (6.8%). Conclusions: Copanlisib is effective in the treatment of relapsed or refractory NHL, with a higher rate of response in indolent NHL than aggressive NHL. Hyperglycemia and hypertension were the most common adverse events.
{"title":"Copanlisib in non-Hodgkin's lymphoma and solid tumors: An efficacy and safety analysis","authors":"R. Subedi, U. Joshi, Sagar Gyawali, V. Agrawal, Asmita Parajuli","doi":"10.4993/ACRT.29.85","DOIUrl":"https://doi.org/10.4993/ACRT.29.85","url":null,"abstract":"Introduction: Copanlisib is an intravenous pan-class I PI3K inhibitor with predominant activity against the α and δ isoforms. We conducted this review to assess the efficacy and safety of copanlisib in patients with relapsed or refractory nonHodgkin’s lymphoma (NHL) and other solid tumors. Methods: A systematic search of the electronic database (PubMed, Cochrane, Clinicaltrials.gov, Google scholar, and China National Knowledge Infrastructure) was conducted for relevant studies. Any clinical trial with clear outcome measures on the efficacy or safety of copanlisib in NHL or other solid tumors were eligible for inclusion. The objective response rate (ORR) and the complete response (CR) rate were used to assess the efficacy. Incidence of all grade and grade 3–4 treatmentemergent adverse events (TEAE) were calculated to evaluate the safety profile. Results: We analyzed seven single-arm prospective clinical trials. The pooled ORR was 39.1% (95% CI: 21.0–60.7%) for NHL cohort. The pooled CR rate for NHL was 10.9% (95% CI: 6.9–16.8%). Indolent NHL had a higher rate of response than aggressive NHL (ORR 56.9% vs. 22.8%; CR rate 15.8% vs. 7.6%). The pooled incidence rate of grade 3–4 TEAE was 73.9% (95% CI: 66.4–80.3%). Most common grade 3–4 TEAE were: hyperglycemia (31.4%), hypertension (29.8%), neutropenia (18.3%), anemia (7.4%), and pneumonia (6.8%). Conclusions: Copanlisib is effective in the treatment of relapsed or refractory NHL, with a higher rate of response in indolent NHL than aggressive NHL. Hyperglycemia and hypertension were the most common adverse events.","PeriodicalId":35647,"journal":{"name":"Annals of Cancer Research and Therapy","volume":" ","pages":""},"PeriodicalIF":0.0,"publicationDate":"2021-01-08","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"44123631","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
L. Yunusova, T. Aoyama, G. Ikramov, Bakhodir Halmanov, J. Sakamoto, Hurriyat Kurbanbaeva
Background: The present study attempted to clarify the typical anatomical variants of Thyroglossal cysts (TGC). Patients and methods: Clinically and epidemiologically 67 previously non-experienced patients with TGC 1.5 to 73.0 years old were examined. Results: Based on clinical and ultrasound examinations of 121 patients with 67 thyroglossal cysts, the most typical cyst of anatomical variations was specified. It was noted that, concerning the hyoid bone, thyroglossal cysts may be suprahyoid (located at the root of the tongue), parahyoid (broadly adjoining the hyoid), prelingual (located in the front of the hyoid in the hypo lingual region), postlingual (located behind the hyoid bone in the prenatal and peri-laryngeal spaces), or sublingual (located the book from the hyoid bone). An ultrasound examination facilitated the identification of thyroglossal cysts without clinical manifestations (23 sublingual cysts among 37 [62.2%] were incidentally revealed by the ultrasound examina- tion), which is important when selecting the most appropriate surgical treatment. Conclusion: Ultrasound studies facilitate the identification of TGCs located at the root of the tongue without any clinical manifestations, which is important when determining the degree of surgical treatment to perform.
{"title":"ULTRASOUND IMAGING OF THYROGLOSSAL CYSTS OF THE NECK TO THE HYOID BONE","authors":"L. Yunusova, T. Aoyama, G. Ikramov, Bakhodir Halmanov, J. Sakamoto, Hurriyat Kurbanbaeva","doi":"10.4993/ACRT.29.30","DOIUrl":"https://doi.org/10.4993/ACRT.29.30","url":null,"abstract":"Background: The present study attempted to clarify the typical anatomical variants of Thyroglossal cysts (TGC). Patients and methods: Clinically and epidemiologically 67 previously non-experienced patients with TGC 1.5 to 73.0 years old were examined. Results: Based on clinical and ultrasound examinations of 121 patients with 67 thyroglossal cysts, the most typical cyst of anatomical variations was specified. It was noted that, concerning the hyoid bone, thyroglossal cysts may be suprahyoid (located at the root of the tongue), parahyoid (broadly adjoining the hyoid), prelingual (located in the front of the hyoid in the hypo lingual region), postlingual (located behind the hyoid bone in the prenatal and peri-laryngeal spaces), or sublingual (located the book from the hyoid bone). An ultrasound examination facilitated the identification of thyroglossal cysts without clinical manifestations (23 sublingual cysts among 37 [62.2%] were incidentally revealed by the ultrasound examina- tion), which is important when selecting the most appropriate surgical treatment. Conclusion: Ultrasound studies facilitate the identification of TGCs located at the root of the tongue without any clinical manifestations, which is important when determining the degree of surgical treatment to perform.","PeriodicalId":35647,"journal":{"name":"Annals of Cancer Research and Therapy","volume":" ","pages":""},"PeriodicalIF":0.0,"publicationDate":"2021-01-08","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"45736136","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Ngoc Cuong Luong, Andrew Nguyen, Hong Anh Vu Thi, Quynh Nhung Bui Thi, Van Du Nguyen
Objectives: We performed this study to determine the early success and outcomes of totally laparoscopic gastrectomy (TLG), dissecting the lower part of the stomach to treat gastric cancer. Materials and Methods: Clinical data, preoperative diagnosis, evaluation of intraoperative lesions, surgical techniques, postoperative pathology, and surgical results of 106 gastric cancer patients who underwent TLG and Billroth II gastrojeju-nal-anastomosis with a Hofmeister-Finsterer reconstruction and D2 lymphadenectomy from January 2019 to August 2020 were recorded and analyzed using SPSS 17.0. We used the Japanese Gastric Cancer Association standards for the clinical and pathological definitions. Results: Of the 106 cases, 76 were males and 30 were females. The average age was 59.33 ± 12.20 years, and the average duration of surgery was 136.37 ± 26.08 minutes. The estimated blood loss was 18.08 ± 10.95 mL. The average length of hospital stay was 8.63 ± 3.89 days. The average post-surgical time to pass flatus was 4.18 ± 1.4 days and that of restarting diet was 3.27 ± 1.08 days. There were no intraoperative complications, and no laparotomy was required. Gastrointestinal anastomosis was performed with Hofmeister-Finsterer reconstruction. General postoperative complications consisted of seven (6.58%) cases: one (0.94%) anastomotic leakage, one (0.94%) gastrojejuno-colic fistula, three (2.82%) early small bowel obstructions, and two (1.89%) late small bowel obstructions. No intra-abdominal bleeding, duodenal stump leakage, pancreatitis, surgical site infections, intra-abdominal abscesses, or fatal cases were recorded. Conclusions: Totally laparoscopic gastrectomy (TLG) treating stomach cancer and D2 lymphadenectomy has shown positive results, with a low postoperative complication rate and safe implementation process to help patients achieve faster recovery and a shorter hospital stay.
{"title":"Laparoscopic gastrectomy with D2 lymphadenectomy for gastric cancer: Short-term results from a tertiary hospital in Vietnam","authors":"Ngoc Cuong Luong, Andrew Nguyen, Hong Anh Vu Thi, Quynh Nhung Bui Thi, Van Du Nguyen","doi":"10.4993/ACRT.29.1","DOIUrl":"https://doi.org/10.4993/ACRT.29.1","url":null,"abstract":"Objectives: We performed this study to determine the early success and outcomes of totally laparoscopic gastrectomy (TLG), dissecting the lower part of the stomach to treat gastric cancer. Materials and Methods: Clinical data, preoperative diagnosis, evaluation of intraoperative lesions, surgical techniques, postoperative pathology, and surgical results of 106 gastric cancer patients who underwent TLG and Billroth II gastrojeju-nal-anastomosis with a Hofmeister-Finsterer reconstruction and D2 lymphadenectomy from January 2019 to August 2020 were recorded and analyzed using SPSS 17.0. We used the Japanese Gastric Cancer Association standards for the clinical and pathological definitions. Results: Of the 106 cases, 76 were males and 30 were females. The average age was 59.33 ± 12.20 years, and the average duration of surgery was 136.37 ± 26.08 minutes. The estimated blood loss was 18.08 ± 10.95 mL. The average length of hospital stay was 8.63 ± 3.89 days. The average post-surgical time to pass flatus was 4.18 ± 1.4 days and that of restarting diet was 3.27 ± 1.08 days. There were no intraoperative complications, and no laparotomy was required. Gastrointestinal anastomosis was performed with Hofmeister-Finsterer reconstruction. General postoperative complications consisted of seven (6.58%) cases: one (0.94%) anastomotic leakage, one (0.94%) gastrojejuno-colic fistula, three (2.82%) early small bowel obstructions, and two (1.89%) late small bowel obstructions. No intra-abdominal bleeding, duodenal stump leakage, pancreatitis, surgical site infections, intra-abdominal abscesses, or fatal cases were recorded. Conclusions: Totally laparoscopic gastrectomy (TLG) treating stomach cancer and D2 lymphadenectomy has shown positive results, with a low postoperative complication rate and safe implementation process to help patients achieve faster recovery and a shorter hospital stay.","PeriodicalId":35647,"journal":{"name":"Annals of Cancer Research and Therapy","volume":" ","pages":""},"PeriodicalIF":0.0,"publicationDate":"2021-01-08","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"48363270","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
M. Rahbaran, S. Baghini, Mahsa Mardasi, Ehsan Razeghian
{"title":"MSCs modifies the proliferation of leukemia MOLT-4 cells and induces their apoptosis through up-regulating Bax, caspase-3, and-8, and down-regulating Bcl-2 expression","authors":"M. Rahbaran, S. Baghini, Mahsa Mardasi, Ehsan Razeghian","doi":"10.4993/ACRT.29.79","DOIUrl":"https://doi.org/10.4993/ACRT.29.79","url":null,"abstract":"","PeriodicalId":35647,"journal":{"name":"Annals of Cancer Research and Therapy","volume":"29 1","pages":"79-84"},"PeriodicalIF":0.0,"publicationDate":"2021-01-08","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"70577710","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
京公网安备 11010802042870号
京ICP备2023020795号-1
扫码关注我们
求助内容：
应助结果提醒方式：